Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor
Annals of Pharmacotherapy · 06.08.2026
DOI: 10.1177/10600280261472893 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 06.08.2026. Verfasst von Lauren Linenfelser und 2 weiteren Autor:innen. Beteiligte Einrichtung: Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Objective
To review the pharmacology, efficacy, and safety of subcutaneous depemokimab-ulaa as add-on therapy in the treatment of severe eosinophilic asthma. Data Sources: PubMed database, Embase, and ClinicalTrials.gov were searched using the following terms: depemokimab, depemokimab-ulaa, Exdensur, and GSK3511294. Study Selection and Data Extraction: Articles published in English between January 2020 and March 2026, related to pharmacology, safety, efficacy, and clinical trials, were reviewed. Four studies met inclusion criteria. Data Synthesis: In phase 3 trials, SWIFT-1 and SWIFT-2, depemokimab-ulaa demonstrated comparable reductions in elevated blood eosinophil (EOS) counts when compared to other interleukin-5 (IL-5) targeting therapies in patients with severe eosinophilic asthma. The annualized exacerbation rates were 0.46 and 0.56 with depemokimab-ulaa vs 1.11 and 1.08 with placebo ( P < .001), respectively. There were no differences in other outcomes that were studied. In the phase 3 NIMBLE trial, depemokimab-ulaa did not meet the noninferiority margin when patients were switched from other anti-IL-5 therapies. Depemokimab-ulaa maintained a favorable safety profile, with no serious adverse events or deaths considered to be related to the drug. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: When compared with other anti-IL-5 agents, depemokimab-ulaa might serve as an effective alternative option with its twice-yearly dosing offering a significant advantage potentially improving patient adherence and clinical outcomes.
Conclusion
Depemokimab-ulaa’s twice-yearly dosing offers a convenient alternative to other anti-IL-5 therapies as add-on treatment for severe eosinophilic asthma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA.
- Henry Ford St. John Hospital, Wayne State University, Detroit, MI, USA.
ORCID-Profile: Lauren Linenfelser, Melissa Lipari, Pramodini Kale-Pradhan
Zitieren
APA
Linenfelser, L., Lipari, M., & Kale-Pradhan, P. (2026). Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261472893
Vancouver
Linenfelser L, Lipari M, Kale-Pradhan P. Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261472893
BibTeX
@article{Linenfelser2026,
author = {Linenfelser, Lauren and Lipari, Melissa and Kale-Pradhan, Pramodini},
title = {Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261472893}
}
EUVIMED